PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
Dallas, TX and San Francisco, CA (August 29, 2022) Pharmaceutical Strategies Group (PSG), an EPIC company, announced an enhancement of its data and analytics platform, Artemetrx®,…
Drug benefit design is increasingly complex. The number of drugs on the market is growing, and decisions about program structure, cost sharing, formulary design, and…
When high-deductible health plans (HDHPs) were introduced in the early 2000s, many expected a new era of healthcare consumerism. HDHPs were expected to foster improved…
Results in PSG’s latest benefit design research reveal an increased focus on member satisfaction DALLAS, Tex. – New research on the latest trends in benefit design launches today. Pharmaceutical…
The latest insights on specialty drug spend and trend across pharmacy and medical benefits The sixth annual State of Specialty Spend and Trend Report analyzes…
At the heart of the investigation: access, pricing, and fair market competition from the six largest vertically integrated pharmacy benefit managers What it is: The…
Employers need to strike the right balance when making decisions about specialty drug benefits. So much of the conversation around specialty drugs, understandably, tend to…
New to market formulary blocks (NTMBs) are increasingly prevalent strategies pharmacy benefit managers (PBMs) are using to control specialty prescription drug costs. NTMBs bar certain newly released…
Employers are navigating a fast-changing landscape of specialty drug benefits. Specialty drug patients now make up 4% of commercially insured member populations as of 2020,…
